Clinical Laserthermia Systems AB (publ)
SSE:CLS-B.ST
0.1015 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 8.273 | 6.268 | 2.245 | 1.332 | 1.426 | 1.808 | 0.614 | 3.637 | 0 | 0 | 0 | 0 | 0.35 | 0.35 | 0.2 | 0.15 |
| Cost of Revenue
| 74.109 | 9.058 | 5.875 | 0.456 | 1.01 | 1.299 | -3.036 | 0.053 | 0.053 | 0 | 0 | 11.394 | 0 | 0 | 0 | 0 |
| Gross Profit
| -65.836 | -2.79 | -3.63 | 0.876 | 0.416 | 0.509 | 3.65 | 3.584 | -0.053 | 0 | 0 | -11.394 | 0.35 | 0.35 | 0.2 | 0.15 |
| Gross Profit Ratio
| -7.958 | -0.445 | -1.617 | 0.658 | 0.292 | 0.282 | 5.941 | 0.985 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 2.13 | 2.13 | 2.104 | 2.376 | 2.376 | 2.015 | 1.718 | 1.541 | 1.897 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 0 | 42.639 | 40.14 | 37.841 | 35.749 | 27.592 | 26.805 | 13.913 | 15.323 | 16.344 | 11.394 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.187 | 2.053 | 0.719 |
| SG&A
| 66.125 | 62.294 | 42.639 | 40.14 | 37.841 | 35.749 | 27.592 | 26.805 | 13.913 | 15.323 | 16.344 | 11.394 | 0 | 5.187 | 2.053 | 0.719 |
| Other Expenses
| 0 | 64.65 | 14.345 | 12.547 | 4.892 | -1.874 | -3.119 | 0.004 | 2.653 | 2.533 | 1.804 | 1.352 | 7.377 | 0.087 | 0.06 | 0.048 |
| Operating Expenses
| 68.478 | 64.65 | 56.984 | 52.687 | 42.733 | 33.875 | 24.474 | 26.809 | 16.566 | 17.856 | 18.148 | 12.746 | 7.377 | 5.274 | 2.112 | 0.767 |
| Operating Income
| -65.836 | -67.442 | -60.682 | -51.811 | -42.317 | -33.451 | -20.88 | -26.899 | -16.599 | -17.915 | -18.148 | -12.746 | -7.027 | -4.923 | -1.912 | -0.617 |
| Operating Income Ratio
| -7.958 | -10.76 | -27.03 | -38.897 | -29.675 | -18.502 | -33.981 | -7.395 | 0 | 0 | 0 | 0 | -20.078 | -14.047 | -9.562 | -4.112 |
| Total Other Income Expenses Net
| -15.039 | -3.823 | -3.459 | -6.128 | -1.058 | 0.507 | -0.441 | -0.14 | -0.029 | 0.015 | -0.177 | 0.049 | 0.052 | -0.03 | -0.065 | -0.054 |
| Income Before Tax
| -80.875 | -71.265 | -64.141 | -57.939 | -43.375 | -32.859 | -21.264 | -26.949 | -16.595 | -17.841 | -18.325 | -12.697 | -6.975 | -4.954 | -1.977 | -0.671 |
| Income Before Tax Ratio
| -9.776 | -11.37 | -28.571 | -43.498 | -30.417 | -18.174 | -34.607 | -7.409 | 0 | 0 | 0 | 0 | -19.928 | -14.133 | -9.886 | -4.475 |
| Income Tax Expense
| -1.083 | -0.576 | 5.879 | 3.271 | 1.275 | -0.004 | -0.002 | -0.14 | -0.028 | 0.057 | 0.005 | 0.065 | 0 | 0 | 0 | 0 |
| Net Income
| -79.792 | -70.66 | -63.615 | -57.939 | -43.375 | -32.855 | -21.263 | -26.949 | -16.595 | -17.841 | -18.325 | -12.697 | -6.975 | -4.954 | -1.977 | -0.671 |
| Net Income Ratio
| -9.645 | -11.273 | -28.336 | -43.498 | -30.417 | -18.172 | -2.58 | -7.409 | 0 | 0 | 0 | 0 | -19.928 | -14.133 | -9.886 | -4.475 |
| EPS
| -23.76 | -169.43 | -221.2 | -262.38 | -250.37 | -207.31 | -150.67 | -233.71 | -163.61 | -209.31 | -214 | -0.74 | -0.14 | -0.11 | -0.043 | -0.023 |
| EPS Diluted
| -23.76 | -169.43 | -221.2 | -262.38 | -250.37 | -207.31 | -150.67 | -233.71 | -163.61 | -209.31 | -214 | -0.74 | -0.14 | -0.11 | -0.043 | -0.023 |
| EBITDA
| -63.128 | -57.814 | -54.948 | -51.612 | -39.419 | -32.552 | -21.024 | -26.895 | -16.541 | -17.743 | -18.027 | -12.562 | -6.94 | -4.836 | -1.853 | -0.569 |
| EBITDA Ratio
| -7.631 | -9.224 | -24.476 | -38.748 | -27.643 | -18.005 | -34.215 | -7.394 | 0 | 0 | 0 | 0 | -19.83 | -13.799 | -9.263 | -3.794 |